Transaction details
Jacqueline Zummo, who serves as Chief Research and Development Officer at Protara Therapeutics, Inc. (NASDAQ: TARA), sold 1,134 shares of the company's common stock on April 8, 2026. The shares were transacted at $5.40 each, producing proceeds of $6,123 according to a Form 4 filed with the Securities and Exchange Commission.
Mechanics of the sale and post-transaction holdings
The filing indicates the sale was executed automatically under a Rule 10b5-1 trading plan that Zummo put in place on December 31, 2025. After the disposition, Zummo's direct ownership in Protara stands at 94,827 shares.
Company valuation and market context
Protara Therapeutics is described in available commentary as carrying a market value of $287 million. InvestingPro analysis places the stock on a most-overvalued list, even as sell-side analysts have maintained price targets in the range of $23 to $30 per share.
Clinical program updates
The insider sale comes alongside fresh interim data from Protara's Phase 2 ADVANCED-2 trial evaluating TARA-002 for non-muscle invasive bladder cancer. In a cohort of 25 patients deemed BCG-unresponsive, the company reported a six-month complete response rate of 68% - a figure consistent with prior disclosures.
Additional trial detail released by the company noted a 12-month complete response rate of 33% among 15 patients. Across 35 evaluable participants, the overall response rate was 68.2% at six months and 33.3% at 12 months. Following publication of the updated interim results, Protara's shares moved lower in after-hours trading.
Warrants and analyst reactions
Protara also confirmed it has met the conditions for exercising common stock purchase warrants that were issued in April 2024, with an exercise price of $5.25 per share. Market watchers continue to assign higher targets: TD Cowen reiterated a Buy rating with a $30.00 target, and JPMorgan initiated coverage with an Overweight rating and a $27.00 target, both citing the company's progress with TARA-002.
What this means for investors
The insider transaction was carried out under an automated plan and left Zummo with a substantial personal holding, while the business simultaneously advanced clinical data and secured the ability to trigger warrant exercise. Analysts' price targets remain materially above the current trading level, and third-party analysis flags the stock as appearing overvalued relative to those targets and current valuation.